Association of β-lactam antimicrobial's exposure with carbapenem-resistant Pseudomonas aeruginosa infection: a cumulative meta-analysis

Prity Rani Deshwal, Muskan Aggarwal, Nalla Surender Reddy, Raisa Fathima, Pramil Tiwari
{"title":"Association of β-lactam antimicrobial's exposure with carbapenem-resistant Pseudomonas aeruginosa infection: a cumulative meta-analysis","authors":"Prity Rani Deshwal,&nbsp;Muskan Aggarwal,&nbsp;Nalla Surender Reddy,&nbsp;Raisa Fathima,&nbsp;Pramil Tiwari","doi":"10.1016/j.glohj.2023.07.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Carbapenems are effective against severe <em>Pseudomonas aeruginosa</em> nosocomial infections. Therefore, carbapenem-resistant <em>Pseudomonas aeruginosa</em> is a serious public health threat. An understanding of the risk of inappropriate exposure to different antimicrobials in resistant <em>Pseudomonas aeruginos</em>a infection could help in elucidating the effective approach towards using antimicrobials in vulnerable patients with CRPA infection.</p></div><div><h3>Object</h3><p>To investigate the association between exposure of β-lactam antimicrobials and CRPA infection relative to control patients.</p></div><div><h3>Methods</h3><p>The MEDLINE/PubMed and OVID/Embase databases were used to search case-control and cohort studies in English language which reported antimicrobial exposure as risk factors for CRPA infection. The pooled odds ratios (<em>OR</em>) were calculated using a random-effect and fixed-effect model, and forest plots from a cumulative meta-analysis method were used to better show how pooled <em>OR</em> changed as updated evidence accumulated.</p></div><div><h3>Results</h3><p>A total of 24 studies comprising 7 039 participants were included for cumulative meta-analysis. A positive correlation was found between development of CRPA infection and exposure of beta-lactam antimicrobials: carbapenems (<em>OR</em> = 7.60, 95% <em>CI</em>: 3.95 to 14.62, <em>P</em> &lt; 0.0001), imipenem (<em>OR</em> = 9.81, 95% <em>CI</em>: 5.56 to 17.33), ampicillin (<em>OR</em> = 1.86, 95% <em>CI</em>: 1.14 to 2.41), piperacillin (<em>OR</em> = 2.82, 95% <em>CI</em>: 1.46 to 2.43), penicillins (<em>OR</em> = 1.42, 95% <em>CI</em>: 0.90 to 2.24), cephalosporins (<em>OR</em> = 1.88, 95% <em>CI</em>: 1.46 to 2.43) and β lactamase inhibitors (<em>OR</em> = 1.96, 95% <em>CI</em>: 1.44 to 2.67). Further, exposure of other antimicrobial agents like quinolone (<em>OR</em> = 2.35, 95% <em>CI</em>: 1.78 to 3.10), ciprofloxacin (<em>OR</em> = 2.35, 95% <em>CI</em>: 1.66 to 3.95), aminoglycoside (<em>OR</em> = 2.17, 95% <em>CI</em>: 1.60 to 2.95), amikacin (<em>OR</em> = 3.11, 95% <em>CI</em>: 2.10 to 4.61), glycopeptides (<em>OR</em> = 3.02, 95% <em>CI</em>: 1.92 to 4.75) and vancomycin (<em>OR</em> = 3.26, 95% <em>CI</em>: 1.48 to 7.18), were also found to be positively associated with development of CRPA infection.</p></div><div><h3>Conclusions</h3><p>Exposure of all kinds of β-lactams is significantly associated with development of carbapenem-resistant <em>Pseudomonas aeruginosa</em> infection. These findings provide an impetus to take a more active approach while using β-lactam antimicrobials in patients with resistant <em>Pseudomonas aeruginosa</em> infections.</p></div>","PeriodicalId":73164,"journal":{"name":"Global health journal (Amsterdam, Netherlands)","volume":"7 3","pages":"Pages 137-146"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global health journal (Amsterdam, Netherlands)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2414644723000702","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Carbapenems are effective against severe Pseudomonas aeruginosa nosocomial infections. Therefore, carbapenem-resistant Pseudomonas aeruginosa is a serious public health threat. An understanding of the risk of inappropriate exposure to different antimicrobials in resistant Pseudomonas aeruginosa infection could help in elucidating the effective approach towards using antimicrobials in vulnerable patients with CRPA infection.

Object

To investigate the association between exposure of β-lactam antimicrobials and CRPA infection relative to control patients.

Methods

The MEDLINE/PubMed and OVID/Embase databases were used to search case-control and cohort studies in English language which reported antimicrobial exposure as risk factors for CRPA infection. The pooled odds ratios (OR) were calculated using a random-effect and fixed-effect model, and forest plots from a cumulative meta-analysis method were used to better show how pooled OR changed as updated evidence accumulated.

Results

A total of 24 studies comprising 7 039 participants were included for cumulative meta-analysis. A positive correlation was found between development of CRPA infection and exposure of beta-lactam antimicrobials: carbapenems (OR = 7.60, 95% CI: 3.95 to 14.62, P < 0.0001), imipenem (OR = 9.81, 95% CI: 5.56 to 17.33), ampicillin (OR = 1.86, 95% CI: 1.14 to 2.41), piperacillin (OR = 2.82, 95% CI: 1.46 to 2.43), penicillins (OR = 1.42, 95% CI: 0.90 to 2.24), cephalosporins (OR = 1.88, 95% CI: 1.46 to 2.43) and β lactamase inhibitors (OR = 1.96, 95% CI: 1.44 to 2.67). Further, exposure of other antimicrobial agents like quinolone (OR = 2.35, 95% CI: 1.78 to 3.10), ciprofloxacin (OR = 2.35, 95% CI: 1.66 to 3.95), aminoglycoside (OR = 2.17, 95% CI: 1.60 to 2.95), amikacin (OR = 3.11, 95% CI: 2.10 to 4.61), glycopeptides (OR = 3.02, 95% CI: 1.92 to 4.75) and vancomycin (OR = 3.26, 95% CI: 1.48 to 7.18), were also found to be positively associated with development of CRPA infection.

Conclusions

Exposure of all kinds of β-lactams is significantly associated with development of carbapenem-resistant Pseudomonas aeruginosa infection. These findings provide an impetus to take a more active approach while using β-lactam antimicrobials in patients with resistant Pseudomonas aeruginosa infections.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
β-内酰胺抗菌素暴露与碳青霉烯耐药铜绿假单胞菌感染的关系:累积荟萃分析
背景碳青霉烯类药物对严重的铜绿假单胞菌医院感染有效。因此,耐碳青霉烯假单胞菌是严重的公共卫生威胁。了解耐药铜绿假单胞菌感染中不适当暴露于不同抗菌素的风险有助于阐明在CRPA感染易感患者中使用抗菌素的有效方法。目的探讨β-内酰胺类抗菌药物暴露与对照组患者CRPA感染的关系。方法使用MEDLINE/PubMed和OVID/Embase数据库检索报告抗菌药物暴露为CRPA感染危险因素的病例对照和英语队列研究。使用随机效应和固定效应模型计算合并优势比(OR),并使用累积荟萃分析方法的森林图来更好地显示合并优势比随更新证据积累的变化情况。结果共纳入24项研究,7039名受试者进行累积荟萃分析。CRPA感染的发生与β -内酰胺类抗菌剂碳青霉烯类的暴露呈正相关(OR = 7.60, 95% CI: 3.95 ~ 14.62, P <0.0001)、亚胺培酮(OR = 9.81, 95% CI: 5.56 ~ 17.33)、氨苄西林(OR = 1.86, 95% CI: 1.14 ~ 2.41)、哌拉西林(OR = 2.82, 95% CI: 1.46 ~ 2.43)、青霉素(OR = 1.42, 95% CI: 0.90 ~ 2.24)、头孢菌素(OR = 1.88, 95% CI: 1.46 ~ 2.43)和β内酰胺酶抑制剂(OR = 1.96, 95% CI: 1.44 ~ 2.67)。此外,暴露于其他抗菌药物如喹诺酮(OR = 2.35, 95% CI: 1.78至3.10)、环丙沙星(OR = 2.35, 95% CI: 1.66至3.95)、氨基糖苷(OR = 2.17, 95% CI: 1.60至2.95)、阿米卡星(OR = 3.11, 95% CI: 2.10至4.61)、糖肽(OR = 3.02, 95% CI: 1.92至4.75)和万古霉素(OR = 3.26, 95% CI: 1.48至7.18)也被发现与CRPA感染的发生正相关。结论各种β-内酰胺暴露与耐碳青霉烯类铜绿假单胞菌感染的发生密切相关。这些发现为在耐药铜绿假单胞菌感染患者中使用β-内酰胺类抗菌剂提供了更积极的途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Global health journal (Amsterdam, Netherlands)
Global health journal (Amsterdam, Netherlands) Public Health and Health Policy
CiteScore
5.00
自引率
0.00%
发文量
0
期刊最新文献
Parsing pathways from chronic illness to self-rated health in Egypt: the role of mental well-being Socioeconomic disparities in outpatient treatment utilization among Indonesian older adults: findings from the 2015 and 2020 National Socioeconomic Survey The impact of private equity investments in Indian healthcare: a critical political economy perspective on equity, access, and rising health costs Healthcare utilization patterns in Indonesia: insights from the 2023 National Socio-economic Survey Heat exposure, physiological strain, and wet bulb globe temperature prediction among outdoor agricultural workers in Pak Chong, Thailand
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1